Sulfasalazine-induced lupus erythematosus.
Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis. After cessation of the sulfasalazine and completion of a six-week course of corticosteroids, these problems resolved over a period of four to six months. It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms. Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.
D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis; D002305:Cardiac Tamponade / Q000139:chemically induced; D003093:Colitis, Ulcerative / Q000188:drug therapy; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*; D008297:Male; D010996:Pleural Effusion / Q000139:chemically induced; D011014:Pneumonia / Q000139:chemically induced; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use
D000974:Antibodies, Antinuclear; D012460:Sulfasalazine